ESMO Congress | Conference

Crizotinib Highly-Effective in ROS1-Rearranged NSCLC

September 29th 2014

Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.

Dr. Weber on Nivolumab Versus Chemotherapy in Advanced Melanoma

September 29th 2014

Jeffrey S. Weber, MD, PhD, discusses the results of a phase III study of nivolumab compared with investigator's choice chemotherapy for the treatment of patients with advanced melanoma after prior anti-CTLA-4 therapy.

Nivolumab Beats Chemotherapy as Second-Line Treatment for Advanced Melanoma

September 29th 2014

Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma, reported Jeffrey Weber, MD, at the 2014 ESMO Congress.

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC

September 29th 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

CLEOPATRA Trial Update Shows Dramatic OS Benefit

September 28th 2014

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

September 28th 2014

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer

September 28th 2014

Cediranib improved response rate and median PFS when added to conventional chemotherapy in a phase II study of patients with relapsed or metastatic cervical cancer.

Pembrolizumab Yields Durable Responses in Advanced NSCLC

September 28th 2014

Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.

Vintafolide Added to Docetaxel Improves Survival in Folate Receptor-Positive NSCLC

September 28th 2014

Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.

Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab

September 28th 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

Anamorelin Improves Appetite, Slows Weight Loss in Lung Cancer

September 27th 2014

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.

Afatinib Improves PFS and Quality of Life in Advanced HNSCC

September 27th 2014

Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.

Dovitinib Meets Primary Endpoint in Phase II Trial of Advanced GIST

September 27th 2014

Dovitinib, an investigational oral tyrosine kinase inhibitor (TKI), demonstrated a "manageable" safety profile while controlling disease in about half of patients with advanced gastrointestinal stromal tumor (GIST) who had discontinued treatment with imatinib due to disease progression or intolerance

Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

September 27th 2014

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

Dr. Petrylak on the Results of the Phase II STRIDE Study

September 27th 2014

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

Bevacizumab Improves Survival in Metastatic Breast Cancer

September 25th 2014

Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.

Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

November 2nd 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

Dr. Markman Discusses the Phase III AURELIA Trial

October 29th 2012

Maurie Markman, MD, from Cancer Treatment Centers of America, discusses the AURELIA trial that examined the addition of bevacizumab to chemotherapy for women with platinum-resistant recurrent ovarian cancer.

Dr. Rotkowitz on Ipilimumab Plus Dacarbazine for Melanoma

October 26th 2012

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Tracking the Oncology Pipeline: Developments From ESMO

October 25th 2012

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

NEXT PAGE
PREVIOUS PAGE